News

bioresorbable stents, dissolving stents, Absorb stent, BVS

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents...

July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to continue the development of a bioresorbable, self-...

Elixir Medical Corp. DESolve 100 CE mark

Elixir Medical Corp. received CE mark approval for its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular scaffold (BVS) in the United States,...

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug...

Micell Technologies Inc. announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials...

Espirt Bioresorbable Vascular Scaffold BVS Peripheral Artery Disease PAD

Six-month results of the ESPRIT trial suggest a bioresorbable drug-eluting scaffold is effective in opening...

Reva Medical ReZolve2 Bioresorbable Scaffold Stent Clinical Trial

An implant of the ReZolve2 bioresorbable scaffold was transmitted live via satellite at the Transcatheter...

Elixir Medical DESolve Bioresorbable Coronary Scaffold System Stents

The first commercial implant of Elixir Medical’s CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany. Elixir’s fully ...

cath lab stents bioresorbable amaranth fortitude scaffold

Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp.

ACC, iPad cardiology apps

DAIC readers chose the following stories as the most popular content in 2013, based on website analytics.

stents bioresorbable cath lab intravascular imaging clinical trial study abbott

The Cardiovascular Research Foundation (CRF) and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced the initiation of the Providing Regional Observations to Study Predictors...

stents bioresorbable fortitude amaranth

Amaranth Medical, a privately held medical device company, presented positive six-month angiographic results from its first-in-human study including patients undergoing percutaneous...

October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

Micell Technologies Inc. announced that a peer reviewed article discussing imaging and clinical results of the...

abbott vascular, abbott laboratories, abbott bioresorbable stents

The Mount Sinai Medical Center is participating in the nationwide Absorb III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary...

July 12, 2013 — Micell Technologies Inc. received CE mark approval for its MiStent sirolimus-eluting absorbable polymer coronary stent system. The MiStent SES is unique in providing local...

Final six and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr. Mark Webster at the late-breaking clinical trials session of the EuroPCR...

Elixer bioresorbable stent

Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve Novolimus-eluting bioresorbable coronary stent scaffold system. The scaffold is...